Philipp Gild
Dr. med.
Philipp Gild
FEBU
  • Wissenschaftlicher Mitarbeiter
  • Facharzt für Urologie
Arbeitsbereich

Kontakt

Standort

Hauptgebäude O10 , 2. Etage
Sprachen
Deutsch (Muttersprache)
Englisch

Fachgebiete

Tätigkeitsschwerpunkte

Publikationen

Zurück
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
Vor

Exploring the intersection of functional recurrence, patient-reported sexual function, and treatment satisfaction after anterior buccal mucosal graft urethroplasty

WORLD J UROL. 2021;2021(doi: 10.1007/s00345-021-03648-y):.

Assessing the Outcome of Holmium Laser Enucleation of the Prostate by Age, Prostate Volume, and a History of Blood Thinning Agents
Gild P, Lenke L, Pompe R, Vetterlein M, Ludwig T, Soave A, Chun F, Ahyai S, Dahlem R, Fisch M, Rink M, Meyer C, Becker A
J ENDOUROL. 2021;2021(doi: 10.1089/end.2020.0605):.

Contemporary national trends in prostate cancer risk profile at diagnosis
Fletcher S, von Landenberg N, Cole A, Gild P, Choueiri T, Lipsitz S, Trinh Q, Kibel A
PROSTATE CANCER P D. 2020;23(1):81-87.

Longitudinal Evaluation of Perineogenital Pain and Postoperative Complications After One-stage Buccal Mucosal Graft Urethroplasty: A Secondary Analysis of a Randomized Controlled Trial
Fuehner C, Vetterlein M, Lesske J, Rink M, Riechardt S, König F, Gild P, Pinnschmidt H, Meyer C, Ludwig T, Engel O, Fisch M, Dahlem R, Soave A
Eur Urol Focus. 2020.

Retrograde Ejaculation After Holmium Laser Enucleation Of The Prostate (HoLEP) - Impact On Sexual Function and Evaluation Of Patient Bother Using Validated Questionnaires
Gild P, Dahlem R, Pompe R, Soave A, Vetterlein M, Ludwig T, Maurer V, Marks P, Ahyai S, Chun F, Lenke L, Ernst T, Fisch M, Rink M, Meyer C, Becker A
ANDROLOGY-US. 2020;8(6):1779-1786.

The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group
Gild P, Vetterlein M, Seiler R, Necchi A, Hendricksen K, Mertens L, Roghmann F, Landenberg N, Gontero P, Cumberbatch M, Dobruch J, Seisen T, Grande P, D'Andrea D, Anract J, Comploj E, Pycha A, Saba K, Poyet C, van Rhijn B, Noon A, Roupret M, Shariat S, Fisch M, Xylinas E, Rink M
SURG ONCOL. 2020;34:312-317.

Validation of the updated eighth edition of AJCC for prostate cancer: Removal of pT2 substages - Does extent of tumor involvement matter?
Pompe R, Neumann T, Kühnke L, Preisser F, Gild P, Tennstedt P, Salomon G, Huland H, Tilki D
UROL ONCOL-SEMIN ORI. 2020;38(7):637.e1-637.e7.

Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy
Soave A, Kluwe L, Yu H, Rink M, Gild P, Vetterlein M, Marks P, Sauter G, Fisch M, Meyer C, Ludwig T, Dahlem R, Minner S, Pantel K, Steinbach B, Schwarzenbach H
SCI REP-UK. 2020;10(1):21562.

Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55-65: Assessing the Morbidity of Multimodal Approaches in Patients with Muscle-invasive Bladder Cancer
Vetterlein M, Gild P, Fisch M, Rink M
EUR UROL. 2020;78(2):e77-e78.

Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index
Vetterlein M, Klemm J, Gild P, Bradtke M, Soave A, Dahlem R, Fisch M, Rink M
EUR UROL. 2020;77(1):55-65.

Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?
Cole A, Ramaswamy A, Harmouch S, Fletcher S, Gild P, Sun M, Lipsitz S, Chiang H, Haider A, Preston M, Kibel A, Trinh Q
Eur Urol Oncol. 2019;2(4):349-354.

Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy
Gild P, Nguyen D, Fletcher S, Cole A, Lipsitz S, Kibel A, Fisch M, Preston M, Trinh Q
CLIN GENITOURIN CANC. 2019;17(3):e488-e493.

Regression Discontinuity Analysis of Salvage Radiotherapy in Prostate Cancer
Gild P, Pompe R, Seisen T, Keeley J, Tang H, Bossi A, Tilki D, Menon M, Abdollah F
Eur Urol Oncol. 2019.

The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy
Marks P, Gild P, Soave A, Janisch F, Minner S, Engel O, Vetterlein M, Shariat S, Sauter G, Dahlem R, Fisch M, Rink M
SURG ONCOL. 2019;28:208-213.

Distal Double Cuff Vs. Transcorporal Cuff as Salvage Options - a Prospective Analysis of Different Artificial Urinary Sphincter (AMS 800) Implantation Sites
Maurer V, Dahlem R, Rosenbaum C, Gild P, Vetterlein M, Schüttfort V, Meyer C, Riechardt S, Fisch M, Marks P, Ludwig T
UROLOGY. 2019;133:234-239.

Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status
McClintock T, von Landenberg N, Cole A, Lipsitz S, Gild P, Sun M, Fletcher S, Roghmann F, Menon M, Nguyen P, Noldus J, Choueiri T, Kibel A, Trinh Q
ANN SURG ONCOL. 2019;26(1):297-305.

Peri-operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer

BJU INT. 2018;121(1):101-110.

Testing the external validity of the EORTC randomized trial 30904 comparing overall survival after radical nephrectomy vs nephron-sparing surgery in contemporary North American patients with renal cell cancer
Abdollah F, Arora S, von Landenberg N, Gild P, Sood A, Dalela D, Trinh Q, Menon M, Rogers C
BJU INT. 2018;121(3):345-347.

The effect of treatment at minority-serving hospitals on outcomes for bladder cancer
Fletcher S, Gild P, Cole A, Vetterlein M, Kibel A, Choueiri T, Sonpavde G, Preston M, Pucheril D, Menon M, Sun M, Lipsitz S, Trinh Q
UROL ONCOL-SEMIN ORI. 2018;36(5):238.e7-238.e17.

Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era
Fletcher S, Harmouch S, Krimphove M, Cole A, Berg S, Gild P, Preston M, Sonpavde G, Kibel A, Sun M, Choueiri T, Trinh Q
WORLD J UROL. 2018;36(11):1767-1774.

Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer
Gild P, Cole A, Krasnova A, Dickerman B, von Landenberg N, Sun M, Mucci L, Lipsitz S, Chun F, Nguyen P, Kibel A, Choueiri T, Basaria S, Trinh Q
J UROLOGY. 2018;200(3):573-581.

Adult iatrogenic ureteral injury and stricture – incidence and treatment strategies
Gild P, Kluth L, Vetterlein M, Engel O, Chun F, Fisch M
Asian J Urol. 2018;5(2):101-106.

Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis
Gild P, Wankowicz S, Sood A, von Landenberg N, Friedlander D, Alanee S, Chun F, Fisch M, Menon M, Trinh Q, Bellmunt J, Abdollah F
UROL ONCOL-SEMIN ORI. 2018;36(10):469.e1-469.e11.

Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy
Landenberg N, Speed J, Cole A, Seisen T, Lipsitz S, Gild P, Menon M, Kibel A, Roghmann F, Noldus J, Sun M, Trinh Q
UROL ONCOL-SEMIN ORI. 2018;36(2):78.e13-78.e19.

Rate and Extent of Pelvic Lymph Node Dissection in the US Prostate Cancer Patients Treated With Radical Prostatectomy
Nocera L, Sood A, Dalela D, Gild P, Rogers C, Peabody J, Montorsi F, Menon M, Briganti A, Abdollah F
CLIN GENITOURIN CANC. 2018;16(2):e451-e467.

Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence
Pompe R, Gild P, Karakiewicz P, Bock L, Schlomm T, Steuber T, Graefen M, Huland H, Tian Z, Tilki D
PROSTATE. 2018;78(9):676-681.

Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages
Pompe R, Tilki D, Preisser F, Leyh-Bannurah S, Bandini M, Marchioni M, Gild P, Tian Z, Fossati N, Cindolo L, Shariat S, Huland H, Graefen M, Briganti A, Karakiewicz P
PROSTATE. 2018;78(10):753-757.

Evaluating Guideline Adherence for T1 Bladder Cancer Treatment and Surveillance: A Retrospective German Multicenter Observation
Vetterlein M, Gild P, Marks P, Roschinski J, Doh O, Höppner W, Wagner W, Isbarn H, Büscheck F, Sauter G, Dahlem R, Soave A, Fisch M, Rink M
UROL INT. 2018;101(3):285-292.

Utilization of pelvic lymph node dissection in patients undergoing robot-assisted radical prostatectomy in India versus the United States - A Vattikuti Collective Quality Initiative database analysis
Abdollah F, Arora S, Jindal T, Gild P, Sood A, Yuvaraja T, Ahlawat R, Gupta N, Bhandari M, Menon M
INDIAN J CANCER. 2017;54(2):421-425.

Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer
Dulz S, Asselborn N, Dieckmann K, Matthies C, Wagner W, Weidmann J, Seidel C, Oing C, Berger L, Alsdorf W, Mankichian B, Meyer C, Vetterlein M, Gild P, Ludwig T, Soave A, Schriefer P, Becker A, Ahyai S, Oechsle K, Bokemeyer C, Wagenfeld L, Fisch M, Hartmann M, Chun F, Kluth L
J CANCER RES CLIN. 2017;143(7):1319-1325.

Immortal-time bias: a crucial yet overlooked confounder in urological research
Fletcher S, Gild P, Trinh Q
BJU INT. 2017;120(4):455.

Editorial Comment
Gild P, Abdollah F
J UROLOGY. 2017;198(2):361.

Editorial Comment
Gild P, Chun F, Becker A
J UROLOGY. 2017;197(4):996-997.

Effect of obesity on bladder cancer and renal cell carcinoma incidence and survival
Gild P, Ehdaie B, Kluth L
CURR OPIN UROL. 2017;27(5):409-414.

Online tools for patient counseling in bladder and kidney cancer-ready for prime time?
Gild P, Rink M, Meyer C
Transl Androl Urol. 2017;6(6):1123-1131.

Racial disparities in prostate cancer treatment—does facility level make a difference?
Gild P, Vetterlein M, Meyer C, Schmid M, Chun F
J XiangYa Med. 2017;2(16):1-2.

Re: Phillip J. Gray, Chun Chieh Lin, Matthew R. Cooperberg, Ahmedin Jemal, Jason A. Efstathiou. Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. Eur Urol 2017;71:729-37
Gild P, von Landenberg N, Cole A
EUR UROL. 2017;71(6):e181-e182.

The effect of AB0 and Rhesus blood grouping systems on oncological outcome in patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma
Rink M, Engel O, Gakis G, Fritsche H, Vetterlein M, Soave A, Peine S, Aziz A, Dahlem R, Stenzl A, Burger M, Shariat S, Fisch M, Gild P
UROL ONCOL-SEMIN ORI. 2017;35(12):671.e17-671.e23.

Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder
Vetterlein M, Roschinski J, Gild P, Marks P, Soave A, Doh O, Isbarn H, Höppner W, Wagner W, Shariat S, Brausi M, Büscheck F, Sauter G, Fisch M, Rink M
Transl Androl Urol. 2017;6(6):1018-1026.

Challenging Residual Contamination of Instruments for Robotic Surgery in Japan
von Landenberg N, Cole A, Gild P, Trinh Q
INFECT CONT HOSP EP. 2017;38(4):501-502.

Factors Influencing Prostate Specific Antigen Testing in the United States
von Landenberg N, Mossanen M, Wang Y, Sammon J, Hanna N, Gild P, Noldus J, Roghmann F, Menon M, Kibel A, Sun M, Chang S, Trinh Q
Urol Pract. 2017;5(6):438-443.

Letzte Aktualisierung aus dem FIS: 28.07.2021 - 00:35 Uhr